Nama's AI scorecard currently rates UFP Technologies Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is UFPT's P/E ratio?

UFP Technologies trades at a trailing price-to-earnings ratio of 28.3.

When does UFPT report earnings?

UFP Technologies's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $2.54.

What is the UFPT price target?

The median analyst price target from 2 analysts is $355.00, with a range of $350.00 – $360.00.

Is UFPT Shariah compliant?

Nama's AAOIFI-style screen reads UFP Technologies as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

UFP Technologies (UFPT)

Healthcare · Medical Devices · NASDAQ

UFP Technologies (UFPT) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $2.35B, a trailing price-to-earnings ratio of 28.3 and a free-cash-flow yield of 3.3%. Over the most recent reported fiscal year, revenue grew 19.5% and free cash flow per share grew 38.4%. Nama's AI scorecard rates it Buy, 6.2 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 6.2/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +31.5% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-17.2%

How far the last close sits under the highest price of the past five years.

Market cap	$2.35B
Trailing P/E	28.3
Price / book	5.1
Price / sales	3.7
FCF yield	3.3%
Dividend yield	—
Gross margin	28.5%
Operating margin	15.2%
Net margin	11.4%
Revenue growth (YoY)	+19.5%
Revenue growth (3-yr annual)	+19.4%
EPS growth (YoY)	+17.1%
FCF/share growth (YoY)	+38.4%
Beta	1.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

UFPT earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate $2.54). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$2.88	$2.69	+7.1%	—
Q2 2026	Aug 3, 2026	$2.92	$2.56	+14.1%	$173.96M
Q1 2026	May 4, 2026	$2.48	$2.31	+7.4%	$154.20M
Q4 2025	Feb 24, 2026	$2.44	$2.24	+8.9%	$148.91M

UFPT analyst price target

Median target $355.00 from 2 analysts, ranging $350.00 – $360.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live UFPT data on Nama Insights →

UFPT FAQ

Is UFPT a buy?: Nama's AI scorecard currently rates UFP Technologies Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is UFPT's P/E ratio?: UFP Technologies trades at a trailing price-to-earnings ratio of 28.3.
When does UFPT report earnings?: UFP Technologies's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $2.54.
What is the UFPT price target?: The median analyst price target from 2 analysts is $355.00, with a range of $350.00 – $360.00.
Is UFPT Shariah compliant?: Nama's AAOIFI-style screen reads UFP Technologies as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.